JP3623975B2 - マルチ薬剤耐性を回避するための医薬品並びにその製造法 - Google Patents

マルチ薬剤耐性を回避するための医薬品並びにその製造法 Download PDF

Info

Publication number
JP3623975B2
JP3623975B2 JP24683493A JP24683493A JP3623975B2 JP 3623975 B2 JP3623975 B2 JP 3623975B2 JP 24683493 A JP24683493 A JP 24683493A JP 24683493 A JP24683493 A JP 24683493A JP 3623975 B2 JP3623975 B2 JP 3623975B2
Authority
JP
Japan
Prior art keywords
drug resistance
avoiding
avoiding multi
isomer
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP24683493A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06312928A (ja
Inventor
エンゲル ユルゲン
クッチャー ベルンハルト
フライシュハウアー イローナ
スツェレーニー シュテファン
メツェナウアー ペーター
ヴェルナー ウルリッヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Aeterna Zentaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG, Aeterna Zentaris GmbH filed Critical Zentaris AG
Publication of JPH06312928A publication Critical patent/JPH06312928A/ja
Application granted granted Critical
Publication of JP3623975B2 publication Critical patent/JP3623975B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP24683493A 1992-10-02 1993-10-01 マルチ薬剤耐性を回避するための医薬品並びにその製造法 Expired - Fee Related JP3623975B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4233113.7 1992-10-02
DE4233113 1992-10-02

Publications (2)

Publication Number Publication Date
JPH06312928A JPH06312928A (ja) 1994-11-08
JP3623975B2 true JP3623975B2 (ja) 2005-02-23

Family

ID=6469448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24683493A Expired - Fee Related JP3623975B2 (ja) 1992-10-02 1993-10-01 マルチ薬剤耐性を回避するための医薬品並びにその製造法

Country Status (18)

Country Link
US (1) US5556856A (https=)
EP (1) EP0590551B1 (https=)
JP (1) JP3623975B2 (https=)
CN (1) CN1088435A (https=)
AT (1) ATE144708T1 (https=)
AU (1) AU666773B2 (https=)
CA (1) CA2107548A1 (https=)
CZ (1) CZ199593A3 (https=)
DE (1) DE59304351D1 (https=)
DK (1) DK0590551T3 (https=)
ES (1) ES2096168T3 (https=)
GR (1) GR3022070T3 (https=)
HU (1) HUT65353A (https=)
MX (1) MX9306120A (https=)
RU (1) RU2106143C1 (https=)
SK (1) SK104493A3 (https=)
UA (1) UA26953C2 (https=)
ZA (1) ZA937315B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EA200801996A1 (ru) * 2006-04-20 2009-04-28 Глаксо Груп Лимитед 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
US20090281086A1 (en) * 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
EP2041087A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
ATE459358T1 (de) * 2006-12-20 2010-03-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor- antagonisten
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2369320T3 (es) * 2007-10-11 2011-11-29 Glaxo Group Limited Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1.
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2011007145A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound as parp inhibitor
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3677322D1 (de) * 1985-11-11 1991-03-07 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
JPH0667844B2 (ja) * 1987-03-06 1994-08-31 エーザイ株式会社 虚血性心疾患の治療・予防剤
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis

Also Published As

Publication number Publication date
CN1088435A (zh) 1994-06-29
DE59304351D1 (de) 1996-12-05
HU9302784D0 (en) 1993-12-28
EP0590551B1 (de) 1996-10-30
ZA937315B (en) 1994-04-22
HUT65353A (en) 1994-05-02
JPH06312928A (ja) 1994-11-08
AU666773B2 (en) 1996-02-22
UA26953C2 (uk) 1999-12-29
RU2106143C1 (ru) 1998-03-10
MX9306120A (es) 1994-04-29
CA2107548A1 (en) 1994-04-03
US5556856A (en) 1996-09-17
ES2096168T3 (es) 1997-03-01
SK104493A3 (en) 1994-08-10
DK0590551T3 (da) 1997-04-21
CZ199593A3 (en) 1994-04-13
AU4876993A (en) 1994-04-14
GR3022070T3 (en) 1997-03-31
EP0590551A3 (https=) 1994-08-31
EP0590551A2 (de) 1994-04-06
ATE144708T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
JP3623975B2 (ja) マルチ薬剤耐性を回避するための医薬品並びにその製造法
Buzsaki et al. Electric activity in the neocortex of freely moving young and aged rats
CN101987849B (zh) 治疗与年龄相关的黄斑变性(amd)的方法
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
US12178811B2 (en) Methods of treating depressive disorders
ES2920132T3 (es) Compuesto de ácido tetrámico 4-oxo-alquilado y método de preparación del mismo
Hester et al. N-[(. omega.-Amino-1-hydroxyalkyl) phenyl] methanesulfonamide derivatives with class III antiarrhythmic activity
SU1545941A3 (ru) Способ получени оксотиазолидиновых соединений
CN105362273B (zh) 7-烷氧基防己诺林碱类化合物在制备治疗和改善抑郁症状的药物中的用途
CN109761958A (zh) 法舒地尔复合盐及其制备方法和用途
JP5204484B2 (ja) リドカインから誘導される化合物、薬学的組成物、使用法、および疾患の治療、予防または抑制の方法
CN118892485A (zh) 凡德他尼及其药学上可接受的盐与硝苯地平及其药学上可接受的盐联合制备治疗癌症和长q-t间期综合症的药物中的用途
KR100545930B1 (ko) 첼리도닌 또는 그 유도체를 포함하는 약제학적 조성물
JP2008501726A6 (ja) リドカインから誘導される化合物、薬学的組成物、使用法、および疾患の治療、予防または抑制の方法
WO2012101440A1 (en) Local anaesthetic
KR20040049307A (ko) 학습능력 및 기억능력의 증진 방법, 및 기억상실의 치료방법
CN113117078A (zh) 一种肿瘤治疗新药物AuNCs@GTTN及其制备方法和应用
TW201835033A (zh) 富勒烯衍生物及其用途
WO2025122626A1 (en) Hydrogen-bonded frameworks nanoparticles for sono-optogenetic treatment of brain diseases
JP2011527290A (ja) ２−（α−ヒドロキシ−ペンチル）安息香酸カリウムを用いたアルツハイマー病の予防と／またおよび／または治療においての役割への適用
SU1676448A3 (ru) Способ получени сульфонамида
CN121081450A (zh) 杜鹃素及其衍生物的新应用
RU2458054C1 (ru) Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью
JP2026513146A (ja) 生体吸収性有機バイオエレクトロニクス
SU1098521A3 (ru) Способ получени производных хиназолина или их солей

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040517

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041129

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees